{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T10:01:47Z","timestamp":1767434507376,"version":"3.48.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,3]]},"DOI":"10.7759\/cureus.100665","type":"journal-article","created":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T10:01:01Z","timestamp":1767434461000},"source":"Crossref","is-referenced-by-count":0,"title":["Atypical Interplay of Dermatomyositis, Metastatic Caecal Carcinoma, and Connective Tissue Disease"],"prefix":"10.7759","author":[{"given":"Yi Ru","family":"Tan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saileesh","family":"Gunasekaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melvin","family":"Chua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2025.4824","article-title":"A novel tool for predicting malignant disease in adult patients with dermatomyositis","author":"Ye J","year":"2025","unstructured":"Ye J, Wu W, Wu H, et al.. A novel tool for predicting malignant disease in adult patients with dermatomyositis. JAMA Dermatol. 2025, 10.1001\/jamadermatol.2025.4824","journal-title":"JAMA Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1503140","article-title":"Risk, risk factors, and screening of malignancies in dermatomyositis: current status and future perspectives","volume":"15","author":"Liu S","year":"2025","unstructured":"Liu S, Zhang Z, Yan S, et al.. Risk, risk factors, and screening of malignancies in dermatomyositis: current status and future perspectives. Front Oncol. 2025, 15:1503140. 10.3389\/fonc.2025.1503140","journal-title":"Front Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1402225","article-title":"Inflammatory muscle diseases","volume":"372","author":"Dalakas MC","year":"2015","unstructured":"Dalakas MC. Inflammatory muscle diseases. N Engl J Med. 2015, 372:1734-47. 10.1056\/NEJMra1402225","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(24)00267-4","article-title":"Idiopathic inflammatory myopathies related lung disease in adults","volume":"13","author":"Sehgal S","year":"2025","unstructured":"Sehgal S, Patel A, Chatterjee S, et al.. Idiopathic inflammatory myopathies related lung disease in adults. Lancet Respir Med. 2025, 13:272-88. 10.1016\/S2213-2600(24)00267-4","journal-title":"Lancet Respir Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-011-0169-7","article-title":"Malignancy in myositis","volume":"13","author":"Zahr ZA","year":"2011","unstructured":"Zahr ZA, Baer AN. Malignancy in myositis. Curr Rheumatol Rep. 2011, 13:208-15. 10.1007\/s11926-011-0169-7","journal-title":"Curr Rheumatol Rep"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2018.9409","article-title":"Characteristics and predictors of malignancy in dermatomyositis: analysis of 239 patients from northern China","volume":"16","author":"Liu Y","year":"2018","unstructured":"Liu Y, Xu L, Wu H, Zhao N, Tang Y, Li X, Liang Y. Characteristics and predictors of malignancy in dermatomyositis: analysis of 239 patients from northern China. Oncol Lett. 2018, 16:5960-8. 10.3892\/ol.2018.9409","journal-title":"Oncol Lett"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1177\/1203475416665601","article-title":"Risk of malignancy in dermatomyositis and polymyositis","volume":"21","author":"Qiang JK","year":"2017","unstructured":"Qiang JK, Kim WB, Baibergenova A, Alhusayen R. Risk of malignancy in dermatomyositis and polymyositis. J Cutan Med Surg. 2017, 21:131-6. 10.1177\/1203475416665601","journal-title":"J Cutan Med Surg"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-016-3296-8","article-title":"Malignancy in dermatomyositis and polymyositis: analysis of 192 patients","volume":"35","author":"Fang YF","year":"2016","unstructured":"Fang YF, Wu YJ, Kuo CF, Luo SF, Yu KH. Malignancy in dermatomyositis and polymyositis: analysis of 192 patients. Clin Rheumatol. 2016, 35:1977-84. 10.1007\/s10067-016-3296-8","journal-title":"Clin Rheumatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0094128","article-title":"Factors predicting malignancy in patients with polymyositis and dermatomyostis: a systematic review and meta-analysis","volume":"9","author":"Lu X","year":"2014","unstructured":"Lu X, Yang H, Shu X, et al.. Factors predicting malignancy in patients with polymyositis and dermatomyostis: a systematic review and meta-analysis. PLoS One. 2014, 9:e94128. 10.1371\/journal.pone.0094128","journal-title":"PLoS One"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/biom12010111","article-title":"Update on malignancy in myositis-well-established association with unmet needs","volume":"12","author":"Opinc AH","year":"2022","unstructured":"Opinc AH, Makowska JS. Update on malignancy in myositis-well-established association with unmet needs. Biomolecules. 2022, 12:10.3390\/biom12010111","journal-title":"Biomolecules"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(25)00233-9","article-title":"Advances in the classification and management of idiopathic inflammatory myopathies","volume":"24","author":"Raaphorst J","year":"2025","unstructured":"Raaphorst J, van der Kooi AJ, Mecoli CA, et al.. Advances in the classification and management of idiopathic inflammatory myopathies. Lancet Neurol. 2025, 24:776-88. 10.1016\/S1474-4422(25)00233-9","journal-title":"Lancet Neurol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-022-08922-4","article-title":"Autoantibody markers of increased risk of malignancy in patients with dermatomyositis","volume":"63","author":"Marz\u0119cka M","year":"2022","unstructured":"Marz\u0119cka M, Niemczyk A, Rudnicka L. Autoantibody markers of increased risk of malignancy in patients with dermatomyositis. Clin Rev Allergy Immunol. 2022, 63:289-96. 10.1007\/s12016-022-08922-4","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-eular.2523","article-title":"FRI0303: Autoimmune diseases associated with anti-ku antibodies: a retrospective case series","volume":"75","author":"Giraldo WAS","year":"2016","unstructured":"Giraldo WAS, C. Bouruncle Alaluna, G. Roy Ari\u00f1o, et al.. FRI0303: Autoimmune diseases associated with anti-ku antibodies: a retrospective case series. Ann Rheum Dis. 2016, 75:545. 10.1136\/annrheumdis-2016-eular.2523","journal-title":"Ann Rheum Dis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00541","article-title":"Autoantibodies associated with connective tissue diseases: what meaning for clinicians?","volume":"9","author":"Didier K","year":"2018","unstructured":"Didier K, Bolko L, Giusti D, Toquet S, Robbins A, Antonicelli F, Servettaz A. Autoantibodies associated with connective tissue diseases: what meaning for clinicians?. Front Immunol. 2018, 9:541. 10.3389\/fimmu.2018.00541","journal-title":"Front Immunol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2019.09.014","article-title":"Malignancy and myositis, from molecular mimicry to tumor infiltrating lymphocytes","volume":"29","author":"Selva-O'Callaghan A","year":"2019","unstructured":"Selva-O'Callaghan A, Ros J, Gil-Vila A, Vila-Pijoan G, Trallero-Aragu\u00e1s E, Pinal-Fernandez I. Malignancy and myositis, from molecular mimicry to tumor infiltrating lymphocytes. Neuromuscul Disord. 2019, 29:819-25. 10.1016\/j.nmd.2019.09.014","journal-title":"Neuromuscul Disord"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.10.018","article-title":"Frequent genetic alterations in myositis autoantigen genes in cancer-associated dermatomyositis","author":"Moreno-C\u00e1rdenas AB","year":"2025","unstructured":"Moreno-C\u00e1rdenas AB, Ros J, Gil-Vila A, et al.. Frequent genetic alterations in myositis autoantigen genes in cancer-associated dermatomyositis. Ann Rheum Dis. 2025, 10.1016\/j.ard.2025.10.018","journal-title":"Ann Rheum Dis"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-2352","article-title":"Clinical and organizational factors in the initial evaluation of patients with lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"143","author":"Ost DE","year":"2013","unstructured":"Ost DE, Jim Yeung SC, Tanoue LT, Gould MK. Clinical and organizational factors in the initial evaluation of patients with lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013, 143:e121S-41S. 10.1378\/chest.12-2352","journal-title":"Chest"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-022-06166-3","article-title":"Clinical value of cancer-associated myositis-specific antibodies, anti-transcriptional intermediary factor 1-\u03b3, and anti-nuclear matrix protein 2 antibodies in a retrospective cohort of dermatomyositis\/polymyositis in a Japanese community hospital","volume":"41","author":"Suga T","year":"2022","unstructured":"Suga T, Oiwa H, Ishida M, Iwamoto Y. Clinical value of cancer-associated myositis-specific antibodies, anti-transcriptional intermediary factor 1-\u03b3, and anti-nuclear matrix protein 2 antibodies in a retrospective cohort of dermatomyositis\/polymyositis in a Japanese community hospital. Clin Rheumatol. 2022, 41:2803-8. 10.1007\/s10067-022-06166-3","journal-title":"Clin Rheumatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/art.38093","article-title":"Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1\u03b3","volume":"65","author":"Fiorentino DF","year":"2013","unstructured":"Fiorentino DF, Chung LS, Christopher-Stine L, et al.. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1\u03b3. Arthritis Rheum. 2013, 65:2954-62. 10.1002\/art.38093","journal-title":"Arthritis Rheum"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000043758","article-title":"Robot-assisted surgery for rectal cancer with tumor-associated dermatomyositis during preoperative chemotherapy: a case report and literature review","volume":"104","author":"Sawamura E","year":"2025","unstructured":"Sawamura E, Hamamoto H, Suzuki Y, et al.. Robot-assisted surgery for rectal cancer with tumor-associated dermatomyositis during preoperative chemotherapy: a case report and literature review. Medicine (Baltimore). 2025, 104:e43758. 10.1097\/MD.0000000000043758","journal-title":"Medicine (Baltimore)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/439549-atypical-interplay-of-dermatomyositis-metastatic-caecal-carcinoma-and-connective-tissue-disease","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T10:01:02Z","timestamp":1767434462000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/439549-atypical-interplay-of-dermatomyositis-metastatic-caecal-carcinoma-and-connective-tissue-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,3]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.100665","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,3]]}}}